Stock Traders Purchase High Volume of Zentalis Pharmaceuticals Call Options (NASDAQ:ZNTL)

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) saw some unusual options trading activity on Monday. Traders acquired 3,891 call options on the stock. This represents an increase of 5,886% compared to the average volume of 65 call options.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of ZNTL. Charles Schwab Investment Management Inc. grew its holdings in Zentalis Pharmaceuticals by 0.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 445,823 shares of the company’s stock valued at $6,754,000 after purchasing an additional 3,759 shares during the period. Quest Partners LLC bought a new stake in Zentalis Pharmaceuticals during the fourth quarter valued at $38,000. TD Asset Management Inc increased its stake in Zentalis Pharmaceuticals by 5.2% during the fourth quarter. TD Asset Management Inc now owns 190,168 shares of the company’s stock valued at $2,881,000 after purchasing an additional 9,400 shares during the last quarter. Decheng Capital LLC bought a new stake in Zentalis Pharmaceuticals during the fourth quarter valued at $31,809,000. Finally, Rafferty Asset Management LLC grew its position in shares of Zentalis Pharmaceuticals by 79.4% during the fourth quarter. Rafferty Asset Management LLC now owns 360,125 shares of the company’s stock worth $5,456,000 after acquiring an additional 159,439 shares during the last quarter.

Zentalis Pharmaceuticals Stock Up 13.6 %

Shares of NASDAQ ZNTL opened at $3.68 on Tuesday. The firm has a 50-day moving average price of $3.54 and a 200 day moving average price of $8.62. Zentalis Pharmaceuticals has a 52 week low of $2.83 and a 52 week high of $23.52. The stock has a market capitalization of $261.38 million, a price-to-earnings ratio of -1.11 and a beta of 1.70.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings results on Friday, August 9th. The company reported ($1.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.40). During the same period last year, the firm posted ($1.85) EPS. Equities research analysts expect that Zentalis Pharmaceuticals will post -2.95 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ZNTL. UBS Group lowered shares of Zentalis Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $28.00 to $5.00 in a report on Thursday, June 20th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a research report on Monday, August 12th. Wedbush raised shares of Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price objective on the stock in a research report on Monday, August 12th. Morgan Stanley reissued an “equal weight” rating and set a $8.00 price objective (down from $38.00) on shares of Zentalis Pharmaceuticals in a research report on Tuesday, June 18th. Finally, Oppenheimer restated an “outperform” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a research note on Monday. Seven investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $10.78.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.